ABOUT US
“Targeting the diverse immune, endocrine and metabolic dysfunctions associated with T1D is a crucial step on the path toward a cure for this multifaceted disease”
Marco Infante, MD, PhD, FACN
Affiliate Associate Professor
Department of Surgery, Division of Cellular Transplantation, Clinical Cell Transplant Program, Diabetes Research Institute, University of Miami Miller School of Medicine
Read more
Since 2019, Dr Marco Infante has been collaborating with Prof Camillo Ricordi in the field of pancreatic islet transplantation for the treatment of T1D. He obtained his MD degree with honors at Sapienza University of Rome in 2014. In 2019, he attained the Board Certification in Endocrinology and Metabolic Disorders, with honors, at the University of Rome Tor Vergata. In 2023, he obtained his PhD in Systems and Experimental Medicine, with honors, at the University of Rome Tor Vergata. He is a member of several international scientific organizations, including the Diabetes Research Institute Federation (DRIF), a global alliance of researchers committed to identifying a cure for T1D. He holds the position of Adjunct Professor of Endocrinology and Applied Nutrition in Internal Medicine at UniCamillus – Saint Camillus International University of Health Sciences (Rome, Italy). In recognition of his scientific contributions to the fields of diabetes mellitus and human nutrition, he has been inducted into the Sigma Xi Scientific Research Honor Society and has received the designation as Fellow of the American College of Nutrition (FACN). He serves on the Editorial Board of various international peer-reviewed scientific journals and has authored several publications in international peer-reviewed scientific journals, contributed to numerous invited book chapters and editorials, and given lectures at international diabetes scientific meetings.
Dr Infante is an endocrinologist conducting research in the fields of Clinical Endocrinology, Diabetes Mellitus, Obesity and Metabolic Medicine. Dr Infante’s research interests are mainly centered on pancreatic islet transplantation, diabetes technology, and cell therapies and immunotherapies for the treatment of T1D. Specifically, his research is focused on the distinct immune, endocrine and metabolic dysfunctions associated with T1D. Moreover, Dr Infante’s research aims to investigate the pleiotropic effects of novel incretin analogs in distinct groups of patients, including those with T1D, T2D, obesity, overweight and cardiometabolic diseases.